Acute portal hypertension, as measured by rapid rise in hepatic venous pressure gradient (HVPG) can lead to further dreaded complications, including acute variceal bleeding (AVB) AVB: 6-week mortality rates of around 15-20% in patients with chronic liver disease without ACLF.The overall prevalence of UGH in cirrhotic patients with AD was 34.4% and 35.7% in patients with ACLF.AVB is a well-recognized precipitant leading to the occurrence and development of ACLF. AVB is a well-recognized precipitant leading to the occurrence and development of ACLF. Medical therapy for esophageal variceal bleeding (EVB) aims to reduce the splanchnic blood flow and portal pressure. The most common vasoactive agents include terlipressin, vasopressin, somatostatin, and octreotide.
Adult patients (age ≥ 18 years) diagnosed with ACLF presenting with due to esophageal varices bleeding.
Age < 18 years
History of coronary heart disease or ventricular arrhythmia,
Stroke or transient ischemic attack,
Bronchial asthma,
Parallel
Terlipressin Injectable Product
DrugTerlipressin Injectable Product
Hepatic venous Pressure Gradient (HVPG) reduction of more than 10% from baseline at 12-24 hours in both arms.
Failure to control hemostasis
Terlipressin-related complications within 5 days i.e. safety of the drug
Number of blood transfusions at 5 days
Rebleed within 42 day
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
